CIML NK Cells With Venetoclax for AML

This trial is testing whether adding specially engineered natural killer (NK) immune cells (called CIML NK cells) to venetoclax — a targeted cancer drug — can help people with acute myeloid leukemia (AML) who are in remission but still have signs of remaining cancer (called measurable residual disease, or MRD). The goal is to use the immune cells to eliminate those last remaining cancer cells before they cause a relapse. **You may be eligible if...** - You are 18 years or older with a confirmed diagnosis of AML - You are currently being treated with azacitidine or decitabine plus venetoclax and have completed at least 1 cycle - Your AML has specific high-risk genetic features suggesting a higher chance of relapse - You are in reasonable health (ECOG ≤ 2) with adequate organ function **You may NOT be eligible if...** - You have had a prior allogeneic stem cell transplant, organ transplant, or prior CAR-T or NK cell therapy - You are HIV-positive or have active uncontrolled hepatitis B or C - You have an active autoimmune disease requiring significant steroids - You are pregnant or breastfeeding - You have a history of Grade 2 or higher hemolytic anemia Talk to your doctor to see if this trial is right for you.